Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

NCT05394103 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Metastatic Cancer

Interventions

DRUG: Q901
DRUG: KEYTRUDA® (pembrolizumab)

Sponsor

Qurient Co., Ltd.

Collaborators

[object Object]